Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 280 No 7502 p586
17 May 2008

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Demos highlights importance of talking to patients

Pharmacists expected to fill in the blanks left by GPs

The nature of conversations that pharmacists have with their patients was also considered in the Demos report.

Pharmacists who contributed told researchers that their conversational role with patients is in flux.

They said the profession is increasingly expected to fill in the blanks after patients have consulted their GP.

The report says: “The power relationship is less well established than with a doctor so conversations [with a pharmacist] can be more exploratory. …Where once they would be the source of information about medicines, pharmacists are now increasingly arbiters of conversation with an informed public.”

The conversations the profession has with patients, especially on hospital wards, is today “more open and honest than those that people feel they should be having with doctors”, says the report.

Concordance, rather than compliance, should underpin conversations pharmacists have with patients about their medicines, a report published this week by the think tank Demos recommends.

Access to information on the internet makes patients more informed about their medicines and, coupled with the Government’s choice agenda, patients increasingly expect to negotiate decisions about their medicines, says the report called “The talking cure: why conversation is the future of healthcare”.

But replacing “compliance” with “concordance” in the NHS vocabulary has little to do with political correctness and requires a “fundamental rethink” about the health professional and patient relationship, the document points out.

“Concordance involves recognising patients’ expertise rather than just finding medicines to fit their chaotic lives,” the report says. “It asks professionals to agree goals with patients rather than assume them. It asks that the role of the patient in decisions and ongoing care is brought to the fore.”

Concordance also creates an opportunity to give the debate around choice more force because it suggests that patients should be intimately involved in choosing the things that matter to them — such as treatment and care plans — and rejecting the things that they think are less important, the report says.

If concordance is allowed to rise to the top of the medicines agenda it would have a profound effect on the development of health services and new medicines, Demos suggests.

The focus, Demos says, would change from one that concentrated on developing ever more powerful drugs to one, which is already emerging, centred on improving patient information and patient decision aids.

Demos refers to an editorial in the BMJ (11 October 2003), which said that “concordance doesn’t come easy” but adds: “Given that compliance, coercion and other approaches have routinely failed, it is worth working out how to make concordance work.”

The report’s author Jack Stilgoe said at its launch: “Patients are becoming experts too and the NHS needs to acknowledge this and listen to them. As Lord Darzi puts the finishing touches to his review on the future of the NHS the focus should be less about the mechanics of the system and more about the people who are at the heart of healthcare.”

Among its recommendations Demos suggests that GPs and patients with chronic conditions should establish “outcome statements” that spell out shared goals; patients with long-term conditions should be given personal budgets to design their own package of healthcare.

They should also be given patient packs detailing what they can expect from consultations, what their rights are and what kind of questions to ask healthcare professionals to ensure they get the most out of their care.

The think tank also calls on the Government to create what it calls “Wikirecords” — online accessible patient records that patients can contribute to and comment on.

Back to Top


©The Pharmaceutical Journal